The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Structural basis for receptor binding heterogeneity of apolipoprotein E from type III hyperlipoproteinemic subjects.
Open accessAbstract
The three major isoforms of human apolipoprotein E (apo-E2, -E3, and -E4) are coded for by three alleles (epsilon 2, epsilon 3, and epsilon 4) which have a common genetic locus. Previously, we demonstrated that E2, E3, and E4 differ in primary structure from one another at two substitution sites, site A (residue 112) and site B (residue 158). At sites A/B, apo-E2, -E3, and -E4 contain cysteine/cysteine, cysteine/arginine, and arginine/arginine, respectively. We demonstrated that the substitution of cysteine for arginine at site B is at least partly responsible for the defective binding of apo-E2 to human fibroblast low density lipoprotein receptors, compared to the normal binding activity of apo-E3 or -E4. Subjects with the genetic disorder type III hyperlipoproteinemia are phenotypically homozygous for apo-E2, but the binding activity of apo-E to the fibroblast receptor differs considerably from one type III individual to another. We therefore undertook a partial comparative sequence analysis of apo-E2 from three type III subjects whose apo-E displayed this heterogeneity. The subject with the poorest binding apo-E2 was genotypically homozygous for an apo-E allele (epsilon 2); cysteine was found at sites A and B. The subject with the most active apo-E2 was genotypically homozygous for an apo-E allele (epsilon 2); cystine was found at site A and at a new site (site C, residue 145). The epsilon 2 allele specifies a protein that has arginine at site B (residue 158); the epsilon 2 allele specifies a protein that has arginine at site C (residue 145). Therefore, the two alleles differ from one another by cysteine/arginine interchanges at two positions, sites B and C. The third subject, whose apo-E2 displayed binding activity intermediate between the activities of the other two, was genotypically heterozygous, having one epsilon 2 allele and one epsilon 2 allele. The intermediate binding activity of apo-E2 from this subject resulted from having a mixture of severely defective apo-E (specified by epsilon 2) and slightly defective apo-E (specified by epsilon 2).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Three variants ofapo E2 have been described.Each ofthese differs from apo E3 by a single amino acid substitution (6, 12- 14).”
From Apolipoprotein E2-Christchurch (136 Arg----Ser). New variant of human apolipoprotein E in a patient with type III hyperlipoproteinemia. (1987) · cites this paper as [14]
In the citing paper
“The most common has a mutation of 158 Arg --Cys (13), but mutations of 145 Arg -* Cys (14) and 146 Lys --Gln (6) have also been reported in individuals with type III hyperlipoproteinemia.”
From Apolipoprotein E2-Christchurch (136 Arg----Ser). New variant of human apolipoprotein E in a patient with type III hyperlipoproteinemia. (1987) · cites this paper as [14]
In the citing paper
“Homozygosity and heterozygocity for the apoE variant apoE3[R145C] has also been associated with severe type III HLP [30], [31].”
From Biophysical Analysis of Apolipoprotein E3 Variants Linked with Development of Type III Hyperlipoproteinemia (2011) · cites this paper as [30]
In the citing paper
“and the 22-kDa domain of lipid-bound apoE3[R145C] has 48% reduced HSPG binding capacity compared to apoE3-22kDa [30], [32].”
From Biophysical Analysis of Apolipoprotein E3 Variants Linked with Development of Type III Hyperlipoproteinemia (2011) · cites this paper as [30]
In the citing paper
“Binding studies showed that lipid-bound apoE3[R145C] has 55% reduced LDL receptor binding capacity compared to apoE3”
From Biophysical Analysis of Apolipoprotein E3 Variants Linked with Development of Type III Hyperlipoproteinemia (2011) · cites this paper as [30]
In the citing paper
“Still, these variants not only maintain their ability to predispose to type III HLP, but also do so in a dominant fashion, unlike apoE2 [22], [26], [30], [31], [33], [34], [35].”
From Biophysical Analysis of Apolipoprotein E3 Variants Linked with Development of Type III Hyperlipoproteinemia (2011) · cites this paper as [30]
In the citing paper
“In contrast, all apoE3 variants studied here demonstrate stronger LDL receptor binding compared to wild-type apoE2 [28], [30], [34], [35].”
From Biophysical Analysis of Apolipoprotein E3 Variants Linked with Development of Type III Hyperlipoproteinemia (2011) · cites this paper as [30]
In the citing paper
“While heterozygosity for three further mutants (apoE2(145 Arg→Cys) (32, 33), apoE2(146 Lys→Gln) (34), or apoE2-Christchurch(136 Arg→Ser) (18, 33)) is associated with type III hyperlipoproteinemia, there are no family studies to ascertain whether these variants also demonstrate a dominant mode of inheritance.”
From Apolipoprotein E3-Leiden contains a seven-amino acid insertion that is a tandem repeat of residues 121–127 (1989) · cites this paper as [32]
In the citing paper
“Prior studies [7][8][9] and Alzheimer Disease Sequencing Project (ADSP) data have shown that R145C is always in phase with ε3 and R150H is always in phase with ε2.”
From Association of African Ancestry–Specific APOE Missense Variant R145C With Risk of Alzheimer Disease (2023) · cites this paper as [8]
Citations
Cites
Weisgraber, K. H., Rall, S. C., & Mahley, R. W. (1981) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)52510-8 · Cited by 777
Self-citationHuman apolipoprotein E. The complete amino acid sequence
Rall, S. C., Weisgraber, K. H., & Mahley, R. W. (1982) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)34702-1 · Cited by 741
Self-citationWeisgraber, K. H., Innerarity, T. L., & Mahley, R. W. (1982) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)34954-8 · Cited by 673
Self-citationZannis, V. I., & Breslow, J. L. (1981) · Biochemistry · doi:10.1021/bi00507a059 · Cited by 563
Innerarity, T. L., & Mahley, R. W. (1978) · Biochemistry · doi:10.1021/bi00601a013 · Cited by 433
Self-citationSherrill, B. C., Innerarity, T. L., & Mahley, R. W. (1980) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)85951-3 · Cited by 426
Self-citationPolymorphism of apolipoprotein E
Utermann, G., Vogelberg, K. H., Steinmetz, A., Schoenborn, W., Pruin, N., Jaeschke, M., Hees, M. T. I. W. S.-V., & Canzler, H. (1979) · Clinical Genetics · doi:10.1111/j.1399-0004.1979.tb02027.x · Cited by 408
Lipoprotein binding to canine hepatic membranes. Metabolically distinct apo-E and apo-B,E receptors.
Hui, D. Y., Innerarity, T. L., & Mahley, R. W. (1981) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)69254-9 · Cited by 383
Self-citationMahley, R. W., Hui, D. Y., Innerarity, T. L., & Weisgraber, K. H. (1981) · Journal of Clinical Investigation · doi:10.1172/jci110365 · Cited by 373
Self-citation(1981) · PubMed · Cited by 341
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 345
Relation of Apolipoprotein E Polymorphism to Lipid Metabolism in Obese Children
Parlier, G., Thomas, G., Bereziat, G., Fontaine, J. L., & Girardet, J.-P. (1997) · Pediatric Research · doi:10.1203/00006450-199705000-00013 · Cited by 18
Mailly, F., Davignon, J., & Nestruck, A. C. (1990) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)42769-5 · Cited by 19
Stavljenić-Rukavina, A., Sertić, J., Salzer, B., Dumić, M., Radica, A., Fumić, K., & Krajina, A. (1993) · Clinica Chimica Acta · doi:10.1016/0009-8981(93)90152-t · Cited by 19
The charge polymorphism of rat apoprotein E.
Reardon, C. A., Driscoll, D. M., Davis, R. A., Borchardt, R. A., & Getz, G. S. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)38549-6 · Cited by 19
de Knijff, P., van den Maagdenberg, A. M. J. M., Boomsma, D. I., Stalenhoef, A. F. H., Smelt, A. H. M., Kastelein, J. J. P., Marais, A. D., Frants, R. R., & Havekes, L. M. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117443 · Cited by 19
Human apolipoprotein E glycosylation and sialylation: from structure to function
Moon, H.-J., Luo, Y., Chugh, D., & Zhao, L. (2024) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2024.1399965 · Cited by 18
Apolipoproteína E e a doença de Alzheimer
Ojopi, E. P. B., Bertoncini, A. B., & Dias‐Neto, E. (2004) · Archives of Clinical Psychiatry (São Paulo) · doi:10.1590/s0101-60832004000100005 · Cited by 19
Imari, Y., Shunichi, K. O. G. A., & Ibayashi, H. (1988) · Metabolism · doi:10.1016/0026-0495(88)90189-8 · Cited by 18
Abou Ziki, M. D., Strulovici-Barel, Y., Hackett, N. R., Rodriguez-Flores, J. L., Mezey, J. G., Salit, J., Radisch, S., Hollmann, C., Chouchane, L., Malek, J., et al. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.09.021 · Cited by 21
Kato, A., Naitou, H., Namioka, M., Akimoto, M., Ishii, T., Sakakibara, H., Shimoi, K., Nakayama, T., & Ohashi, N. (2010) · Bioscience Biotechnology and Biochemistry · doi:10.1271/bbb.90897 · Cited by 17
Gylling, H., Relas, H., & Miettinen, T. A. (1995) · Atherosclerosis · doi:10.1016/0021-9150(94)05495-5 · Cited by 17
Ebert, D. L., Maeda, N., Lowe, S. W., Hasler‐Rapacz, J., Rapacz, J., & Attie, A. (1988) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38429-7 · Cited by 17
The Genetics of Alzheimer Disease and the Application of Molecular Tests
Tobin, S. L., Chun, N., Powell, T., & McCONNELL, L. M. (1999) · Genetic Testing · doi:10.1089/gte.1999.3.37 · Cited by 17
Dilliott, A. A., Sunderland, K. M., McLaughlin, P. M., Roberts, A., Evans, E. C., Abrahão, A., Binns, M. A., Black, S. E., BORRIE, M. J., Casaubon, L. K., et al. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.04.011 · Cited by 18
Increased serum remnant lipoproteins in patients with apolipoprotein E7 (apo ESuita)
Yanagi, K., Yamashita, S., Hiraoka, H., Ishigami, M., Kihara, S., Hirano, K.-I., Sakai, N., Nozaki, S., Funahashi, T., Kameda-Takemura, K., et al. (1997) · Atherosclerosis · doi:10.1016/s0021-9150(96)06068-6 · Cited by 16
Mulder, M. T., van der Boom, H., de Knijff, P., Braam, C., van den Maagdenberg, A. M. J. M., Leuven, J. A. G., & Havekes, L. M. (1994) · Atherosclerosis · doi:10.1016/0021-9150(94)90113-9 · Cited by 16
Tercé, F., Milne, R. W., WEECH, P. K., Davignon, J., & Marcel, Y. L. (1985) · Arteriosclerosis An Official Journal of the American Heart Association Inc · doi:10.1161/01.atv.5.2.201 · Cited by 16
Apolipoprotein E haplotyping by denaturing high-performance liquid chromatography
Poli, M., Gatta, L. B., Dominici, R., Lovati, C., Mariani, C. B., Albertini, A., & Finazzi, D. (2005) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2005.090 · Cited by 16
Patsch, W., Patsch, J. R., & Gotto, A. M. (1989) · Medical Clinics of North America · doi:10.1016/s0025-7125(16)30643-5 · Cited by 14
Kitahara, M., Shinomiya, M., Shirai, K., Saitō, Y., & Yoshida, S. (1990) · Atherosclerosis · doi:10.1016/0021-9150(90)90041-g · Cited by 15
Pharmacological treatment of lipid disorders in diabetes mellitus
Lopes-Virella, M. F., & Colwell, J. A. (1987) · Diabetes/Metabolism Reviews · doi:10.1002/dmr.5610030305 · Cited by 15
Yamanouchi, Y., Arinami, T., Tsuchiya, S., Miyazaki, R., Takaki, H., Takano, T., & Hamaguchi, H. (1994) · Japanese journal of human genetics · doi:10.1007/bf01874050 · Cited by 15
Karet, F. E., & Lifton, R. P. (1997) · Journal of the American Society of Nephrology · doi:10.1681/asn.v85840 · Cited by 15
Triglycerides, hypertension, and smoking predict cardiovascular disease in dysbetalipoproteinemia
Paquette, M., Bernard, S., Paré, G., & Baass, A. W. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.12.006 · Cited by 14
Apolipoprotein polymorphism and multifactorial hyperlipidaemia
Utermann, G. (1988) · Journal of Inherited Metabolic Disease · doi:10.1007/bf01800572 · Cited by 14
LDL receptor binds newly synthesized apoE in macrophages: a precursor pool for apoE secretion
Zhao, Y., & Mazzone, T. (1999) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)33506-9 · Cited by 14
Familial Lipoprotein Disorders in Patients with Premature Coronary Artery Disease
Ordovás, J. M., Wilson, P. W. F., Salem, D. N., Genest, J. J., & Schaefer, E. J. (1993) · Medical science symposia series · doi:10.1007/978-94-011-1703-6_44 · Cited by 14
Jensen, T. G., Roses, A. D., & Jørgensen, A. L. (1994) · Neuroscience Letters · doi:10.1016/0304-3940(94)90519-3 · Cited by 14
Apolipoprotein E phenotypes in hyperlipidaemic patients and their implications for treatment
Janus, E. D., Grant, S., Lintott, C. J., & Wardell, M. R. (1985) · Atherosclerosis · doi:10.1016/0021-9150(85)90038-3 · Cited by 15
Idenitification and characterization of a new variant of apolipoprotein E (apo E-Kochi).
SUEHIRO, T., YOSHIDA, K., YAMANO, T., & OHNO, F. (1990) · Japanese Journal of Medicine · doi:10.2169/internalmedicine1962.29.587 · Cited by 17
Overexpression of apolipoprotein E4 increases kainic-acid-induced hippocampal neurodegeneration
Zhang, X., Mao, X., Zhang, H., Zheng, X., Pham, T. M., Adem, A., Winblad, B. G., Mix, E., & Zhu, J. (2011) · Experimental Neurology · doi:10.1016/j.expneurol.2011.10.024 · Cited by 13
Genetic susceptibility to traumatic brain injury and apolipoprotein E gene
Sun, X., & Jiang, Y. Q. (2008) · Chinese Journal of Traumatology · doi:10.1016/s1008-1275(08)60051-6 · Cited by 13
Molecular genetics of lipoprotein disorders.
Breslow, J. L. (1984) · Circulation · doi:10.1161/01.cir.69.6.1190 · Cited by 13
Processing of rat liver apoprotein E primary translation product.
Reardon, C. A., Hay, R., Gordon, J. I., & Getz, G. S. (1984) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37808-1 · Cited by 13
Expression analysis of apolipoprotein E and its associated genes in gastric cancer
Shi, X., Xu, J., Wang, J., Cui, M., Gao, Y., Niu, H., & Jin, H. (2015) · Oncology Letters · doi:10.3892/ol.2015.3447 · Cited by 12
Weisgraber, K. H., Newhouse, Y. M., Taylor, J. M., Tuan, B., Nestruck, A. C., Davignon, J., & Mahley, R. W. (1989) · Arteriosclerosis An Official Journal of the American Heart Association Inc · doi:10.1161/01.atv.9.1.50 · Cited by 12
Self-citationSinnott, B. P., & Mazzone, T. (2006) · Endocrine Practice · doi:10.4158/ep.12.2.183 · Cited by 12
Cassel, D., Phillips, M. C., Rostron, P. L., Rothblat, G. H., & Utermann, G. (1984) · Atherosclerosis · doi:10.1016/0021-9150(84)90119-9 · Cited by 12
The Apo E-System: Genetic Control of Plasma Lipoprotein Concentration
Utermann, G. (1986) · Springer eBooks · doi:10.1007/978-1-4684-1262-8_23 · Cited by 12
Molecular biology in arteriosclerosis research.
Williams, D. L. (1985) · Arteriosclerosis An Official Journal of the American Heart Association Inc · doi:10.1161/01.atv.5.3.213 · Cited by 12
Apolipoprotein A-I of primates.
Nicolosi, R. J., & Zannis, V. I. (1984) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37726-9 · Cited by 12
Research progress on exosomal proteins as diagnostic markers of gastric cancer (review article)
Su, H., Ren, W., & Zhang, D. (2022) · Clinical and Experimental Medicine · doi:10.1007/s10238-022-00793-5 · Cited by 11
The metabolic basis of familial hypercholesterolaemia
Myant, N. B. (1983) · Journal of Molecular Medicine · doi:10.1007/bf01488153 · Cited by 11
Bradley, W. A., Booyse, F. M., & Gianturco, S. H. (1994) · Atherosclerosis · doi:10.1016/0021-9150(94)90151-1 · Cited by 11
Prevalence and clinical correlates of beta-migrating very-low-density lipoprotein
Knopp, R. H., Walden, C. E., HEISS, G. M., Johnson, J. L., & WAHL, P. W. (1986) · The American Journal of Medicine · doi:10.1016/0002-9343(86)90305-0 · Cited by 11
Purification of biologically active apolipoproteins by chromatofocussing
McLeod, R. S., Lacko, A. G., Pritchard, P. H., & Frohlich, J. J. (1986) · Journal of Chromatography B Biomedical Sciences and Applications · doi:10.1016/s0378-4347(00)83593-8 · Cited by 11
Vialettes, B., Reynier, P., Atlan-Gepner, C., Mekki, N., Lesluyes, L., Luc, G., Lairon, D., & Malthièry, Y. (2000) · British Journal Of Nutrition · doi:10.1017/s0007114500000787 · Cited by 10
Crystal Structures of the Common Apolipoprotein E Variants: Insights into Functional Mechanisms
Wardell, M. R., Wilson, C., Agard, D. A., Mahley, R. W., & Weisgraber, K. H. (1993) · Springer eBooks · doi:10.1007/978-3-642-84634-2_8 · Cited by 10
Self-citationAmino acid sequence of human plasma apolipoprotein C‐III from normalipidemic subjects
Hospattankar, A. V., Brewer, H. B., Ronan, R., & Fairwell, T. (1986) · FEBS Letters · doi:10.1016/0014-5793(86)80300-3 · Cited by 10
Demacker, P. N. M., Bredie, S. J. H., Vogelaar, J. M., Hectors, M. P. C., van Heijst, P. J., Stuyt, P. M. J., & Stalenhoef, A. F. H. (1998) · Atherosclerosis · doi:10.1016/s0021-9150(98)00035-5 · Cited by 10
Smit, M., de Knuff, P., Frants, R. R., Klasen, E. C., & Havekes, L. M. (1987) · Clinical Genetics · doi:10.1111/j.1399-0004.1987.tb03298.x · Cited by 10
Additive Effect of APOE Rare Variants on the Phenotype of Familial Hypercholesterolemia
Marmontel, O., Abou-Khalil, Y., Bluteau, O., Cariou, B., Carreau, V., Charrière, S., Divry, E., Gallo, A., Moulin, P., Paillard, F., et al. (2023) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.123.319146 · Cited by 9
Rare apolipoprotein E variant identified in a patient with Type III hyperlipidaemia
Wenham, P. R., McDowell, I., Hodges, V. M., McEneny, J., O’Kane, M., Jérémy, R., Davies, H., Nicholls, D. P., Trimble, E. R., & Blundell, G. (1993) · Atherosclerosis · doi:10.1016/0021-9150(93)90028-s · Cited by 9
Lee, S., Grosskopf, I., Choi, S. Y., & Cooper, A. D. (2004) · Journal of Lipid Research · doi:10.1194/jlr.m400284-jlr200 · Cited by 10
Venkatramana, P., Reddy, P. C., & Ferrell, R. E. (2001) · International Journal of Human Genetics · doi:10.1080/09723757.2001.11885746 · Cited by 9
Novel molecular mechanisms in Alzheimer’s disease: The potential role of DEK in disease pathogenesis
Greene, A. N., Solomon, M. B., & Vinnedge, L. M. P. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1018180 · Cited by 8
Elliott, D. A., Kim, W. S., Jans, D. A., & Garner, B. (2007) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2007.10.021 · Cited by 8
Diabetes and lipoprotein receptors
Kraemer, F. B. (1987) · Diabetes/Metabolism Reviews · doi:10.1002/dmr.5610030301 · Cited by 7
Feussner, G., Albanese, M., & Valencia, A. (1996) · Atherosclerosis · doi:10.1016/0021-9150(96)05870-4 · Cited by 7
A novel apolipoprotein E5 variant with a 24-bp insertion causing hyperlipidemia
Yamanouchi, Y., Takano, T., Hamaguchi, H., & Tokunaga, K. (2001) · Journal of Human Genetics · doi:10.1007/s100380170014 · Cited by 8
Touré, M., Diouf, N. N., Thiam, S., Diop, J. P. D., Coly, M. S., Mbengue, A., Sar, F. B., Bâ, A., Diallo, F. A., & Samb, A. (2022) · Cureus · doi:10.7759/cureus.24063 · Cited by 7
Zhong, Z., Wu, H., Wu, H., & Zhao, P. (2018) · Genetics and Molecular Biology · doi:10.1590/1678-4685-gmb-2017-0301 · Cited by 8
Analytical procedures for the detection and characterization of apolipoprotein E mutants
Assmann, G., Funke, H., & Jabs, H.-U. (1987) · American Heart Journal · doi:10.1016/0002-8703(87)90639-9 · Cited by 7
Groß, W., & März, W. (1999) · Analytica Chimica Acta · doi:10.1016/s0003-2670(98)00497-8 · Cited by 7
Kawashiri, M., Higashikata, T., Takata, M., Katsuda, S., Miwa, K., Nohara, A., Inazu, A., Kobayashi, J., Shimizu, M., Koizumi, J., et al. (2005) · Circulation Journal · doi:10.1253/circj.69.746 · Cited by 8
Chapter 12 Lipoprotein genetics and molecular biology
Breslow, J. L. (1987) · New comprehensive biochemistry · doi:10.1016/s0167-7306(08)60206-9 · Cited by 7
Apolipoproteins, Quantitative Lipoprotein Traits and Multifactorial Hyperlipidaemia
Utermann, G. (2007) · Novartis Foundation symposium · doi:10.1002/9780470513507.ch5 · Cited by 7
Relation Between Apolipoprotein E Phenotype and the Changes in Lipids During Tamoxifen Treatment.
Hozumi, Y., Kawano, M., Saito, T., & Miyata, M. (1998) · Endocrine Journal · doi:10.1507/endocrj.45.255 · Cited by 7
Regulation of cholesterol synthesis and the potential for its pharmacologic manipulation
Davis, R. A., Sinensky, M. S., & Junker, L. H. (1989) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(89)90119-8 · Cited by 7
Fat and Lipid Metabolism and the Involvement of Apolipoprotein E in Alzheimer's Disease
Hone, E., Lim, F., & Martins, I. J. (2019) · Wiley eBooks · doi:10.1002/9781119356752.ch7 · Cited by 8
Apolipoprotein E: Receptor Binding Properties
Weisgraber, K. H., Innerarity, T. L., Rall, S. C., & Mahley, R. W. (1985) · Springer eBooks · doi:10.1007/978-1-4613-2459-1_13 · Cited by 7
Self-citationAlcalá, A., Morell, M., & Ríus, F. (2001) · Revista Española de Cardiología · doi:10.1016/s0300-8932(01)76525-6 · Cited by 6
Apolipoprotein E3Basel: new insights into a highly conserved protein region
Miserez, A. R., Scharnagl, H., Muller, P. Y., Mirsaidi, R., Stähelin, H. B., Monsch, A. U., März, W., & Hoffmann, M. M. (2003) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.2003.01180.x · Cited by 5
Monoclonal antibodies to serum lipoproteins: Their present and future use in biology and medicine
Watt, R. M., Carhart, R. L., Gentile, T., & Watt, T. S. (1985) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(85)90081-6 · Cited by 5
(2001) · PubMed · Cited by 5
Brunzell, J. D., Chait, A., Albers, J. J., Foster, D. M., Failor, R. A., & Bierman, E. L. (1987) · American Heart Journal · doi:10.1016/0002-8703(87)90637-5 · Cited by 5
Frequency of Apolipoprotein A-I Mutants in the German Population
Assmann, G., Menzel, H. J., Kladetzky, R. G., & Büttner, G. (1984) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.1984.22.9.585 · Cited by 5
Human Plasma Lipoprotein Metabolism
Pownall, H. J., Rosales, C., Gillard, B. K., Moon, J. E., & Gotto, A. M. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-28786-9.00001-3 · Cited by 4
Triglyceride-Rich Lipoproteins
Le, N., & Brown, W. V. (2010) · Springer eBooks · doi:10.1007/978-1-4419-5839-6_4 · Cited by 5
Genetic Forms of Dyslipidemia in Children
DRASH, A. L. (1991) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1991.tb43732.x · Cited by 4
Rall, S. C., Innerarity, T. L., Weisgraber, K. H., Wardell, M. R., & Mahley, R. W. (1990) · Springer eBooks · doi:10.1007/978-94-009-0731-7_10 · Cited by 4
Self-citationImmunological discrimination between the human apolipoprotein E2(Arg158—-Cys) and E3 isoforms.
Gerritse, K., de Knijff, P., van Ierssel, G., Havekes, L. M., Frants, R. R., Schellekens, M. M., Zegers, N. D., Claassen, E., & Boersma, W. (1992) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)41547-0 · Cited by 4
Plasma Apolipoproteins: Gene Structure, Function, and Variants
Scanu, A. M. (1987) · Elsevier eBooks · doi:10.1016/b978-0-12-568405-7.50009-6 · Cited by 4
Guen, Y. L., Belloy, M. E., Eger, S. J., Chen, A. W., Kennedy, G., Thornton, T. A., Farrer, L. A., Napolioni, V., He, Z., & Greicius, M. D. (2021) · medRxiv · doi:10.1101/2021.10.20.21265141 · Cited by 4
Polymorphism of Apo lipoprotein E gene and the risk of multiple sclerosis.
Hamid, M., Sabzghabaee, A. M., Mousavian, Z., Saadatnia, M., Shirani, S., & Moazen, F. (2011) · PubMed Central · Cited by 3
Takahashi, K., Hikita, M., Taira, K., Kobayashi, J., Bujo, H., & Saitō, Y. (2001) · Internal Medicine · doi:10.2169/internalmedicine.40.1015 · Cited by 3
Human Plasma Lipoprotein Metabolism
Pownall, H. J., & Gotto, A. M. (2009) · Elsevier eBooks · doi:10.1016/b978-141605469-6.50005-6 · Cited by 3
Familial disorders of plasma apolipoproteins
Sirtori, C. R., & Franceschini, G. (1985) · Journal of Molecular Medicine · doi:10.1007/bf01747977 · Cited by 3
Yamamoto, A., Yamamura, T., & Tajima, S. (1990) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1990.tb42276.x · Cited by 4
Effects of apolipoprotein E polymorphism on the development of stroke.
Ahmad, U., Mahmood, M. S., Siddiqui, S., & Pm, F. (2004) · PubMed · Cited by 3
Apolipoprotein E Mutants, Hyperlipidemia and Arteriosclerosis
Utermann, G. (1985) · Drugs Affecting Lipid Metabolism VIII · doi:10.1007/978-1-4613-2459-1_14 · Cited by 24
The role of ligand-receptor interactions in disease
Vermeer, B. J., & Leuven, J. A. G. (1990) · Journal of Dermatological Science · doi:10.1016/0923-1811(90)90216-z · Cited by 2
Nuzzo, R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601981103 · Cited by 2
Apolipoprotein E Polymorphism in Sheep
Tsunoda, K., Yamamoto, Y., Akiya, Y., Sato, K., RAJBHANDARY, H. B., Son, H. V., & Loc, C. B. (1998) · Biochemical Genetics · doi:10.1023/a:1018753714783 · Cited by 2
Valeur sémiologique des apolipoprotéines
Fruchart, J. (1985) · La Revue de Médecine Interne · doi:10.1016/s0248-8663(85)80076-x · Cited by 2
Rezeptoren im Lipoprotein-Stoffwechsel
Steinmetz, A., & Utermann, G. (1988) · Springer eBooks · doi:10.1007/978-3-662-39609-4_60 · Cited by 2
Plasma Lipoproteins and 3-Hydroxy-3-methylglutaryl-Coenzyme A Reductase: A Status Report
Smith, L. C., & Gotto, A. M. (1985) · Elsevier eBooks · doi:10.1016/b978-0-12-564430-3.50012-8 · Cited by 2
Apolipoprotein E Phenotype and Coronary Atherosclerosis
Etoh, M., Okuda, F., TAKAGI, H., Matsuda, Y., Hideo, F. U. J. I., & Kusukawa, R. (1986) · The Journal of Japan Atherosclerosis Society · doi:10.5551/jat1973.14.1_141 · Cited by 2
Atherosclerosis and Plasma Lipid Transport with Aging
Schonfeld, G. (1984) · Springer eBooks · doi:10.1007/978-1-4612-5272-6_4 · Cited by 2
[The scavenger receptor and its importance in amyloid processes].
Aguilar-Gaytán, R., & Mas‐Oliva, J. (2002) · PubMed · Cited by 1
Metadata
- Authors
- Rall, S. C., Weisgraber, K. H., Innerarity, T. L., & Mahley, R. W.
- ORCID
- Mahley, R W
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 1982-08
- Volume
- 79
- Issue
- 15
- Pages
- 4696-4700
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC346743
- OpenAlex
- W2081151510
- Cited by
- 345
- References
- 16
- Citations by year
- 2024: 7 · 2023: 2 · 2022: 5 · 2021: 5 · 2020: 3 · 2019: 3 · 2018: 2 · 2017: 1 · 2016: 2 · 2015: 6 · 2014: 4 · 2013: 3 · 2012: 7
- FWCI
- 54.05
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- apolipoprotein E, type III hyperlipoproteinemia, LDL receptor, apolipoprotein E isoforms, site-directed mutagenesis, receptor binding activity, genetic polymorphism
- MeSH terms
- Alleles, Amino Acid Sequence, Apolipoproteins, Apolipoproteins E, Genes, Humans, Hyperlipoproteinemia Type III, Receptors, Cell Surface, Low Density Lipoprotein Receptor-Related Protein-1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
